← Leaderboards
Meilan K Han
University Of Michigan At Ann Arbor
$16,787,558
Attributed
$36,613,766
Total exposure
10
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.6M · FY2009–25$10M$7.5M$5M$2.5M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$36,613,766 · 10
By mechanism
R01$33,186,493 · 6
U01$1,562,161 · 1
K24$1,086,160 · 1
K23$552,699 · 1
R21$226,253 · 1
Top collaborators
- Fernando J Martinez16 shared
- Charles R Hatt6 shared
- Jeffrey L Curtis5 shared
- Eric A Hoffman5 shared
- Prescott G Woodruff5 shared
- Craig J Galban4 shared
- Umadevi Sivanappa Sajjan1 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Umadevi Sivanappa Sajjan$7,641,515
- James J. Moon$14,172,333
- Jeffrey L Curtis$10,027,931
- Robert Pickett Dickson$8,802,133
- Robert C Hyzy$5,668,847
Others in their field
Top investigators on “Lung”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$372,040,227
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$201,818,043
- Walter John Curran · Thomas Jefferson University$112,093,071
Research focus
LungSmokerChronic Obstructive Airway DiseaseDisease ProgressionCohortResponseX-Ray Computed TomographyPulmonary EmphysemaSymptomsFundingCharacteristicsSpirometryImageBaseChestPathologicSmall Airways DiseaseSiteNational Heart, Lung, And Blood InstituteHeterogeneityPhysiologicalLesionTargeted TreatmentStaging
Grant awards (47)
Leveraging Quantitative Imaging from Lung Cancer Screening to Create Tools to Confront COPD$672,974
R01 · FY2025 · HL · contact PI
Defining Pathways in COPD Patient Oriented Research$122,735
K24 · FY2025 · HL · contact PI
Understanding the Origins of Early COPD$2,168,770
R01 · FY2024 · HL
Leveraging Quantitative Imaging from Lung Cancer Screening to Create Tools to Confront COPD$626,247
R01 · FY2024 · HL · contact PI
Defining Pathways in COPD Patient Oriented Research$122,771
K24 · FY2024 · HL · contact PI
Understanding the Origins of Early COPD$2,101,189
R01 · FY2023 · HL
Prediction of COPD Progression by PRM$686,225
R01 · FY2023 · HL · contact PI
Defining Pathways in COPD Patient Oriented Research$122,805
K24 · FY2023 · HL · contact PI
Understanding the Origins of Early COPD$2,241,348
R01 · FY2022 · HL
Prediction of COPD Progression by PRM$686,225
R01 · FY2022 · HL · contact PI
Defining Pathways in COPD Patient Oriented Research$122,839
K24 · FY2022 · HL · contact PI
Understanding the Origins of Early COPD$2,263,283
R01 · FY2021 · HL
The CAPTURE Study: Validating a unique COPD screening tool in primary care$1,983,602
R01 · FY2021 · HL
Prediction of COPD Progression by PRM$686,225
R01 · FY2021 · HL · contact PI
Defining Pathways in COPD Patient Oriented Research$119,002
K24 · FY2021 · HL · contact PI
Understanding the Origins of Early COPD$2,499,040
R01 · FY2020 · HL
The CAPTURE Study: Validating a unique COPD screening tool in primary care$2,056,934
R01 · FY2020 · HL
Prediction of COPD Progression by PRM$700,225
R01 · FY2020 · HL · contact PI
Redefining Therapy In Early COPD: RETHINC$200,000
U01 · FY2020 · HL · contact PI
Defining Pathways in COPD Patient Oriented Research$119,002
K24 · FY2020 · HL · contact PI
The CAPTURE Study: Validating a unique COPD screening tool in primary care$2,062,326
R01 · FY2019 · HL
Defining Pathways in COPD Patient Oriented Research$119,002
K24 · FY2019 · HL · contact PI
The CAPTURE Study: Validating a unique COPD screening tool in primary care$2,213,604
R01 · FY2018 · HL
Defining the role of early pulmonary vascular disease in COPD$717,271
R01 · FY2018 · HL
Redefining Therapy In Early COPD: RETHINC$324,359
U01 · FY2018 · HL · contact PI
Defining Pathways in COPD Patient Oriented Research$119,002
K24 · FY2018 · HL · contact PI
The CAPTURE Study: Validating a unique COPD screening tool in primary care$2,419,738
R01 · FY2017 · HL
Defining the role of early pulmonary vascular disease in COPD$730,205
R01 · FY2017 · HL
Parametric Response Mapping in COPD$687,186
R01 · FY2017 · HL · contact PI
Redefining Therapy In Early COPD: RETHINC$333,077
U01 · FY2017 · HL · contact PI
Parametric Response Mapping in COPD$272,378
R01 · FY2017 · HL · contact PI
Defining Pathways in COPD Patient Oriented Research$119,002
K24 · FY2017 · HL · contact PI
Parametric Response Mapping in COPD$1,001,078
R01 · FY2016 · HL · contact PI
Defining the role of early pulmonary vascular disease in COPD$738,217
R01 · FY2016 · HL
Redefining Therapy In Early COPD: RETHINC$341,229
U01 · FY2016 · HL · contact PI
Defining the role of early pulmonary vascular disease in COPD$152,500
R01 · FY2016 · HL
Parametric Response Mapping in COPD$903,303
R01 · FY2015 · HL · contact PI
Defining the role of early pulmonary vascular disease in COPD$790,711
R01 · FY2015 · HL
Redefining Therapy In Early COPD: RETHINC$363,496
U01 · FY2015 · HL · contact PI
Parametric Response Mapping in COPD$110,438
R01 · FY2015 · HL · contact PI
Parametric Response Mapping in COPD$1,015,251
R01 · FY2014 · HL · contact PI
Beneficial effects of quercetin in COPD - a preliminary clinical trial$226,253
R21 · FY2013 · AT
Impact of Gender on Symptoms and Progression of IPF$55,156
K23 · FY2013 · HL · contact PI
Impact of Gender on Symptoms and Progression of IPF$126,157
K23 · FY2012 · HL · contact PI
Impact of Gender on Symptoms and Progression of IPF$126,592
K23 · FY2011 · HL · contact PI
Impact of Gender on Symptoms and Progression of IPF$123,729
K23 · FY2010 · HL · contact PI
Impact of Gender on Symptoms and Progression of IPF$121,065
K23 · FY2009 · HL · contact PI